Literature DB >> 12885816

Cognitive outcome of long-term survivors of multisystem langerhans cell histiocytosis: a single-institution, cross-sectional study.

Vasanta Rao Nanduri1, Leasha Lillywhite, Claire Chapman, Louise Parry, Jon Pritchard, Faraneh Vargha-Khadem.   

Abstract

PURPOSE: Damage to the CNS, including the cerebellum, and to the hypothalamopituitary axis, is documented in Langerhans cell histiocytosis (LCH). Neuropsychologic deficits have been recognized, but this is the first study in which cognitive function has been systematically assessed in a cohort of patients. PATIENTS AND METHODS: Twenty-eight long-term survivors of multisystem LCH (mean age, 15.1 years) were investigated for intelligence, memory and learning, language, and academic attainments.
RESULTS: The mean intelligence quotient (IQ) of the entire group was not significantly different from the mean of the population (ie, mean +/- SD, 100 +/- 1), but there were wide ranges (Full-Scale IQ [FSIQ]: mean, 93.6; range, 61.7 to 134; Performance IQ [PIQ]: mean, 92.2; range, 46 to 136; and Verbal IQ [VIQ]: mean, 93.7; range, 64.2 to 126). CNS involvement was a significant risk factor for lower scores, but sex, diabetes insipidus, and cranial radiotherapy were not. The CNS group had lower VIQ, PIQ, and FSIQ than patients with no CNS involvement (no CNS group: mean +/- SD FSIQ, 102.3 +/- 15.6; CNS group: mean +/- SD FSIQ, 73.6 +/- 7.7; P <.001). A similar pattern of results was obtained for all other cognitive measures. Even when effects of reduction in FSIQ were taken into account, specific deficits were found in patients in the CNS group.
CONCLUSION: Long-term survivors of multisystem LCH, particularly patients with CNS involvement, may develop significant cognitive deficits. All patients should have formal, repeated neuropsychologic assessment as part of long-term follow-up, which will enable abnormalities to be detected early so that appropriate supportive measures can be offered.

Entities:  

Mesh:

Year:  2003        PMID: 12885816     DOI: 10.1200/JCO.2003.05.048

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

1.  The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis.

Authors:  Loïc Le Guennec; Caroline Decaix; Jean Donadieu; Maria Santiago-Ribeiro; Nadine Martin-Duverneuil; Richard Levy; Daniel Delgadillo; Aurélie Kas; Aurélie Drier; Laurent Magy; Eleonore Bayen; Khe Hoang-Xuan; Ahmed Idbaih
Journal:  J Neurol       Date:  2014-05-22       Impact factor: 4.849

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

3.  18F-FDG PET in neurodegenerative Langerhans cell histiocytosis : results and potential interest for an early diagnosis of the disease.

Authors:  Maria-João Ribeiro; Ahmed Idbaih; Caroline Thomas; Philippe Remy; Nadine Martin-Duverneuil; Yves Samson; Jean Donadieu; Khê Hoang-Xuan
Journal:  J Neurol       Date:  2008-01-31       Impact factor: 4.849

4.  Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis.

Authors:  Elena Sieni; Carmen Barba; Marzia Mortilla; Sara Savelli; Laura Grisotto; Gianpiero Di Giacomo; Katiuscia Romano; Claudio Fonda; Annibale Biggeri; Renzo Guerrini; Maurizio Aricò
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.